Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 2,503 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,503 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $30,861.99. Following the transaction, the insider now owns 159,357 shares of the company's stock, valued at $1,964,871.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $12.56, for a total transaction of $31,437.68.
• On Monday, April 15th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.95, for a total transaction of $34,916.85.
• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total value of $965,130.57.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $0.84 during trading on Tuesday, reaching $13.74. 8,711,816 shares of the company's stock were exchanged, compared to its average volume of 5,298,561. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $17.16. The company has a market cap of $2.95 billion, a P/E ratio of -1,374.00 and a beta of 0.97. The firm's 50-day moving average price is $13.94 and its 200 day moving average price is $10.57.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business's quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.18 EPS for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Forerunner Ventures Management LLC bought a new position in shares of Hims & Hers Health during the fourth quarter worth about $86,836,000. M&G Plc bought a new position in Hims & Hers Health during the 1st quarter worth approximately $8,232,000. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company's stock worth $88,857,000 after purchasing an additional 428,671 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Hims & Hers Health by 39.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,272,750 shares of the company's stock valued at $8,006,000 after purchasing an additional 357,590 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in shares of Hims & Hers Health by 38.6% during the third quarter. Federated Hermes Inc. now owns 1,032,452 shares of the company's stock worth $6,494,000 after buying an additional 287,552 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HIMS. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a "buy" rating and a $20.00 price target for the company. Jefferies Financial Group restated a "hold" rating and set a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Seaport Res Ptn reiterated a "buy" rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Guggenheim boosted their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Finally, Truist Financial raised their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a "hold" rating in a research note on Tuesday, February 27th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.08.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.